The IF1 inhibitor protein of the mitochondrial F1F0-ATPase  by Green, David W & Grover, Gary J
Review
The IF1 inhibitor protein of the mitochondrial F1F0-ATPase
David W. Green a;*, Gary J. Grover b
a 3-Dimensional Pharmaceuticals, Inc., 665 Stockton Drive, Suite 104, Exton, PA 19341, USA
b Metabolic Diseases Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA
Received 26 May 1999; received in revised form 10 November 1999; accepted 10 November 1999
Abstract
Recent studies on the IF1 inhibitor protein of the mitochondrial F1F0-ATPase from molecular biochemistry to possible
pathophysiological roles are reviewed. The apparent mechanism of IF1 inhibition of F1F0-ATPase activity and the
biophysical conditions that influence IF1 activity are summarized. The amino acid sequences of human, bovine, rat and
murine IF1 are compared and domains and residues implicated in IF1 function examined. Defining the minimal inhibitory
sequence of IF1 and the role of conserved histidines and conformational changes using peptides or recombinant IF1 is
reviewed. Luft’s disease, a mitochondrial myopathy where IF1 is absent, is described with respect to IF1 relevance to
mitochondrial bioenergetics and clinical observations. The possible pathophysiological role of IF1 in conserving ATP under
conditions where cells experience oxygen deprivation (tumor growth, myocardial ischemia) is evaluated. Finally, studies
attempting to correlate IF1 activity to ATP conservation in myocardial ischemic preconditioning are compared. ß 2000
Elsevier Science B.V. All rights reserved.
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1. Introduction
The mitochondrial F1F0-ATPase (EC 3.6.1.34) is
arguably the most important enzyme in the body as
it synthesizes the majority of the cell’s energy cur-
rency, ATP. The enzyme is made up of two domains,
the inner membrane F0 domain and the catalytic F1
domain, which protrudes from the F0 domain into
the mitochondrial matrix. The synthesis of ATP re-
quires an electrochemical proton gradient across the
inner mitochondrial membrane, which is created by
inner membrane respiratory proteins that transport
protons out of the matrix as electrons from metabol-
ic substrates are transferred to oxygen. ATP synthe-
sis catalyzed by the F1 domain is driven by the trans-
port of protons back into the matrix through the F0
domain. When a cell is deprived of oxygen, the elec-
trochemical gradient across the inner membrane col-
lapses and the F1F0-ATPase switches its catalytic
activity from ATP synthesis to ATP hydrolysis. In
contrast to other ion-motive ATPases such as the
(Na/K)- or Ca2-ATPases, there is no obvious
physiological bene¢t of ATP hydrolysis through the
F1F0-ATPase. The depletion of ATP in tissues that
are deprived of oxygen by lack of blood £ow (ische-
mia) e¡ects that tissue’s ability to recover during
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reperfusion and the mitochondrial F1F0-ATPase has
been implicated as the major consumer of ATP dur-
ing global myocardial ischemia [1].
In 1963, Pullman and Monroy discovered a solu-
ble, heat-stable protein in mitochondria from bovine
heart that inhibits the ATP hydrolase activity of the
F1F0-ATPase [2]. Further in vitro characterization of
this ‘IF1’ protein was consistent with it being active
under the physiological conditions where ATP hy-
drolysis rather than ATP synthesis would occur.
The binding of IF1 to the F1F0-ATPase in submito-
chondrial particles requires the hydrolysis of ATP in
the absence of an electrochemical gradient across the
inner membrane and is optimal at pH 6.7 [3^5], con-
ditions observed in mitochondria from canine hearts
undergoing global ischemia [6]. Similar conditions
might be found in tumor cells, where oxygen levels
vary from the perivascular regions to the anoxic ne-
crotic centers [7]. Thus, IF1 could play an important
role in the pathology of tissue ischemia and tumor
growth by helping conserve ATP under conditions of
oxygen deprivation.
This review will summarize recent studies on IF1
from mammalian mitochondria from molecular bio-
chemistry to possible pathophysiological roles. Fol-
lowing a brief summary of biophysical properties and
the mechanism of IF1 inhibition, the IF1 amino acid
sequences between four di¡erent mammalian sources
will be compared with respect to structure and func-
tion. Attempts to de¢ne the minimal inhibitory se-
quence of IF1 and the signi¢cance of histidines and
conformational changes in IF1 inhibition will be re-
viewed and evaluated. The possible role of IF1 in
mitochondrial myopathy and physiological condi-
tions where cells are deprived of oxygen will be dis-
cussed and recent hypotheses on the role of IF1 in
ischemic preconditioning compared.
2. General mechanistic properties of the IF1 protein
Only a summary of mechanistic studies on IF1 in-
hibition will be presented here since previous review
articles have covered this topic in su⁄cient detail [8^
10]. Although there is experimental evidence that IF1
can inhibit ATP synthesis [11], there is general agree-
ment that IF1 is most active under conditions of
ATP hydrolysis by the F1F0-ATPase. Accordingly,
the mechanism of IF1 inhibition of ATP hydrolysis
by the F1F0-ATPase will be the focus of this section.
IF1 is a reversible non-competitive inhibitor of
ATP hydrolysis by the F1F0-ATPase [12,13] and
binds to the soluble F1 domain in a 1:1 stoichiom-
etry [14^16]. The catalytic F1 domain can be sepa-
rated from the F0 domain under conditions where it
retains its ATP hydrolase activity, but loses the abil-
ity to synthesize ATP [17,18]. The activity of the
soluble F1 domain is dependent upon retaining the
subunits in the K3L3QNO con¢guration; three active
sites are composed of primarily residues from the K
and L subunits [19]. Although yeast IF1 interacts at
the interface of K and L subunits [20], cross-linking
of bovine IF1 to the bovine F1 domain has only
identi¢ed residues 394^459 on the C-terminus of
the L subunit as the binding site [21]. Residues
394^459 are distant from the active site and contain
the ‘DELSEED’ (D = aspartic acid, E = glutamic
acid, L = leucine, S = serine) sequence, which is also
the binding site of quinacrine mustard and several
inhibitory cationic dyes [22^24]. From the high reso-
lution structures of the bovine F1 domain that sup-
port the ‘binding change’ mechanism of catalysis
[19,25,26], it appears the ‘DELSEED’ sequence
would be most accessible to binding a ligand such
as IF1 only in the ‘open’ or ‘LE’ conformation. Ac-
cording to the binding change mechanism, only one
of the three L subunits can be in the open conforma-
tion and the 1:1 binding stoichiometry observed be-
tween IF1 and F1 is consistent with this.
IF1 appears to function by trapping adenine nu-
cleotides within the catalytic sites in the F1 domain.
Under in vitro conditions where the concentration of
ATP approaches the concentration of F1 active sites,
the hydrolytic rate is very slow, representing single or
‘unisite’ catalysis. As the concentration of ATP in-
creases to steady-state conditions, the catalytic rate
increases exponentially due to the binding of nucle-
otide substrate at one site promoting the release of
nucleotide product at another site (‘multisite’ or co-
operative catalysis) [27,28]. Vazquez-Laslop and
Dreyfus [29] showed that the bovine F1 :IF1 enzy-
me:inhibitor complex is capable of slow turnover
unisite hydrolysis of ATP, but there is no increase
beyond the unisite rate when excess ATP is added.
Thus, IF1 could inhibit ATP hydrolysis by binding to
the ‘open’ L subunit and locking the enzyme in a
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conformation where cooperative catalysis is not pos-
sible.
IF1 is more potent against the F1F0-ATPase com-
plex in mitochondrial membranes than against the
soluble F1 domain. Recombinant bovine IF1 has an
IC50 of 34 nM against the ATPase activity in bovine
heart submitochondrial particles using 1 mM ATP at
pH 6.7 and 37‡C [30]. A Ki value of about 200 nM
has been measured for recombinant bovine IF1
against the soluble bovine F1 domain (0.4 mM
ATP at 30‡C) [12]. These values are in good agree-
ment with the potency of IF1 puri¢ed from bovine
heart against the membrane-bound F1F0 complex or
the soluble F1 domain [31]. The elements of the F1F0
membrane complex that contribute to the enhanced
potency of IF1 remain unde¢ned, but a recent study
indicates IF1 interacts with the O subunit of the F1
domain [32]. The exact function of the O subunit is
not known, but it is believed to be important for
coupling the activities of the F1 and F0 domains
[33] and hence could be in di¡erent conformations
between the soluble and F0-bound forms of the F1
domain.
Before IF1 can inhibit the F1F0-ATPase, hydroly-
sis of ATP in the presence of a divalent cation must
occur. A hypothesis based upon binding and kinetic
data proposes that IF1 ¢rst binds to the enzyme in an
unproductive mode and upon hydrolysis of MgWATP
changes to a productive inhibitory orientation [9].
This awaits conformation by structural studies.
Although the requirement of Mg2 has long been
established [13], the role of Zn2 on IF1 activity is
less certain. Zn2 promotes binding of IF1 to rabbit
heart mitochondrial membranes, but prevents inhibi-
tion of ATP hydrolysis by the F1F0-ATPase [34].
However, the signi¢cance of this is not clear as
Zn2 does not have this e¡ect on rat [35] or bovine
[36] IF1.
3. IF1 primary structure
An alignment of the IF1 amino acid sequences
deduced from bovine [37], human [38] and rodent
[39,40] cDNA is shown in Fig. 1. A comparison of
the amino acid sequences deduced from the cDNA
for bovine IF1 or from the puri¢ed protein [41] iden-
ti¢ed an N-terminal presequence of 25 amino acids
[37]. Hereafter ‘mature’ IF1 refers to the sequence in
Fig. 1 beginning with residue ‘1’ and the ‘prese-
quence’ as the preceding 25 amino acids. Human
and rodent IF1 proteins also contain a presequence
that has signi¢cant homology to the bovine IF1 pre-
sequence either by identity or homologous substitu-
tion. Since the IF1 gene is found in the nuclear rather
than the mitochondrial genome, it is assumed that
the presequence is required for transport into the
mitochondria. The exact mechanisms involved in
transporting IF1 into the mitochondria are unknown,
as is whether this process could exert any regulation
over the activity of the F1F0-ATPase.
The molecular mass calculated from the amino
acid sequence of the mature animal IF1 proteins in
Fig. 1 is approx. 10 kDa, which is in good agreement
with the molecular mass estimated by gel electropho-
resis under denaturing conditions of the mature rat
and bovine proteins puri¢ed from tissue [42]. There is
no evidence for posttranslational modi¢cation of IF1
(e.g., phosphorylation, glycosylation). Puri¢ed bo-
vine IF1 has been observed as an aggregated oligo-
mer in aqueous solution [43]. The aggregated state of
IF1 detected by light scattering measurements and
gel ¢ltration methods [30] is surprising given the ami-
no acid composition. The animal IF1 proteins in Fig.
1 contain no cysteines and very few hydrophobic
amino acids. Although the proteins are abundant in
Fig. 1. Amino acid sequence comparison of human [38], rat
[39], and mouse [40] IF1 proteins deduced from the cDNA se-
quence to bovine IF1 [37]. Residues that di¡er from the bovine
sequence are indicated, a blank space means the same residue is
found at that position as in bovine IF1. ‘X’ represents a residue
that was not determinable from the cDNA sequence. Negative
numbers indicates the N-terminal leader sequence; the mature
protein begins at position 1. An asterisk indicates where the
cDNA sequence ended.
BBABIO 44844 22-5-00
D.W. Green, G.J. Grover / Biochimica et Biophysica Acta 1458 (2000) 343^355 345
polar residues the isoelectric points are near neutral,
which could cause aggregation in bu¡ers resembling
physiological conditions. The abundance of polar
residues could also give rise to intermolecular salt
bridges that could result in an aggregated oligomeric
state. However, these e¡ects of polar residues in IF1
proteins are speculative and there is no obvious
physiological relevance for an aggregated or oligo-
meric form of IF1.
The homology between mature IF1 from various
species is not as highly conserved as the amino acid
sequences of the F1F0-ATPase L subunit [44], but
nevertheless is signi¢cant. There is 75% identity be-
tween mature bovine and human IF1, 90% between
rat and murine, and 65% between bovine and mur-
ine. The relevance of the sequence homology to func-
tion is validated by the ability of IF1 from one spe-
cies to inhibit the enzyme from another, including
yeast [42,45,46].
Although the amino acid sequences of IF1 proteins
from yeast and plants can be aligned to the sequen-
ces of the animal IF1 proteins, the degree of homol-
ogy is much less than between the animal IF1 pro-
teins. In addition, the yeast and plant IF1 proteins
have unique properties relative to animal IF1. For
example, the yeast and potato inhibitor proteins are
signi¢cantly smaller than the animal IF1 proteins and
the potato protein does not inhibit the activity of the
bovine F1 domain [47]. The yeast IF1 protein can
cross-react with animal F1 enzymes, but yeast IF1
activity is stabilized by yeast accessory proteins for
which there are no reported animal homologues [48].
Because of these structural and mechanistic di¡eren-
ces, the yeast and plant IF1 proteins will not be dis-
cussed further in this review.
There are two regions of the IF1 proteins that have
been the focus of structure-function studies. The ¢rst
is between residues 20 and 50, which is the most
conserved sequence among animals. The sequence
identity for IF1 residues 20^50 is 90% between bo-
vine and human and 80% between bovine and ro-
dent. It is no surprise that this sequence has been
the focus for de¢ning the minimal inhibitory se-
quence of IF1. The second functional region is a
histidine-rich segment between residues 48 and 70,
which has been implicated in conformational changes
and the pH-dependent activity of the protein. These
topics will be explored in the subsequent sections.
4. The minimal inhibitory sequence of IF1
The incentive to identify the minimal inhibitory
sequence of IF1 is certainly in part to focus on which
parts of the protein are essential for IF1 function.
However, there is also a need to provide a relevant
tool for structural studies since the solubility prob-
lems of puri¢ed mature IF1 referred to in the pre-
vious section have hampered these e¡orts. The ¢rst
reported use of IF1 fragments was in the early 1980s
when proteolytic fragments of bovine IF1 corre-
sponding to residues 10^84 and 16^84 were found
to be active inhibitors of the bovine enzyme [49^
51]. Although this indicated amino terminal residues
were not required for activity, it did not necessarily
de¢ne the minimal inhibitory sequence. Since then,
synthetic peptides and recombinant IF1 fragments
have been used to try and de¢ne the minimal IF1
inhibitory sequence.
The minimal inhibitory sequence of bovine IF1
against the membrane-bound enzyme was systemati-
cally de¢ned based upon the activity of peptides with
truncated amino or carboxyl termini relative to intact
IF1 [30]. Deleting residues 1^17 decreases the potency
of IF1 almost 40-fold, while the potency of peptides
missing residues 1^9 or 1^13 is indistinguishable
from intact IF1. However, the peptide missing resi-
dues 1^13 displays a time-dependent inhibition not
observed with intact IF1. On the carboxyl end, delet-
ing residues 57^84 does not e¡ect IF1 potency, but a
130-fold loss in potency is observed when residues
46^84 are deleted. Therefore, the amino and carboxyl
termini of the minimal inhibitory sequence fall be-
tween residues 9 and 13 and 46 and 57, respectively.
This was further re¢ned using peptides that began at
residue 10 and ended at residue 46 or 47. The po-
tency of peptide 10^47 was not signi¢cantly di¡erent
from intact IF1, but the potency of the 10^46 peptide
was 10-fold less potent than intact IF1. This study
collectively identi¢es the minimal inhibitory sequence
of bovine IF1 as between residues 10 and 47,
although the N-terminus might be shortened between
residues 10 and 17.
Unfortunately, none of the peptides described
above with activity comparable to intact IF1 was
more soluble than the parent protein and did not
agree with results from other laboratories. Papa et
al. [52] found that a peptide corresponding to resi-
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dues 42^58 was as potent as intact bovine IF1 and
Harris [53] found that deleting residues 1^17 actually
increased the inhibitory potency of bovine IF1. Lebo-
witz and Pedersen [54] measured a Ki of 40 WM for
a peptide corresponding to residues 22^45 of rat IF1
against the soluble rat F1 domain. There have also
been di¡erences reported between the activity of pep-
tides corresponding to residues 22^46 of bovine IF1.
The IC50 of peptide 22^46 was measured at about
1 WM by Stout et al. [55] and Papa et al. [52], while
van Raaij et al. [30] could not measure any inhibition
up to 100 WM. All of these studies were done at pH
6.5^6.7 and used peptides whose purity was rigor-
ously determined. van Raaij et al. [30] acknowledged
that the di¡erences could be due to preincubating at
pH 6.7 and assaying at pH 8.0, which could hasten
the dissociation of the peptides relative to the other
groups that preincubated and measured activity at
pH 6.5^6.7. These inconsistencies make it di⁄cult
to arrive at a consensus minimal inhibitory sequence
of IF1 and raise the question as to which assay con-
ditions are relevant.
5. Role of histidines in IF1 function
IF1 is most potent at inhibiting the ATP hydrolase
activity of the F1F0-ATPase complex or the soluble
F1 domain around pH 6.7, with the inhibition dimin-
ishing as the pH is raised to pH 8.0. This type of pH
pro¢le could be consistent with the ionization of his-
tidine. The pH-dependent conformational change of
the yeast IF1 protein can be detected by nuclear
magnetic resonance spectroscopy and is coincident
with the titration of a single histidine residue [56].
As will be discussed in greater detail in the next
section, similar conformational changes have been
measured for animal IF1. Inspection of Fig. 1 shows
that animal IF1 contains ¢ve histidines conserved at
positions 48, 49, 55, 56 and 70. The importance of
the histidines in bovine IF1 has been demonstrated
by chemically modifying the histidines, which abol-
ishes inhibitory activity [57]. However, this method
does not identify which histidines are important for
IF1 activity.
Peptide fragments and site-directed mutagenesis
have been used to investigate the role of histidines
in IF1 function. Papa et al. [52] constructed three
peptides corresponding to residues 42^58 of bovine
IF1 where His-48 and His-49, His-55 and His-56, or
all four histidines were replaced with alanine. All
three peptides were less potent and lost the pH-de-
pendent activity of the ‘wild type’ 42^58 peptide
against the soluble bovine F1 domain or the F1F0
complex. Site-directed mutagenesis was used to
change His-49 in intact bovine IF1 with hydrophilic
or hydrophobic residues, which resulted in little to
no change in the potency of IF1 against ATP hydro-
lysis by the F1 domain at pH 6.7 [36]. Similarly,
replacing His-48 or His-55 in rat IF1 with alanine
had little e¡ect at pH 6.7 [54]. However, all of the
site-directed mutants were more potent than wild
type IF1 against ATP hydrolysis at pH 8.0. These
results indicate histidines at positions 48, 49 and 55
are not required for IF1 activity at pH 6.7, but are
required for the pH-dependent decrease in IF1 activ-
ity between pH 6.7 and 8.0. Given the increased ac-
tivity of the mutant IF1 proteins at pH 8.0, it would
be interesting to see if they can inhibit ATP synthesis
by the F1F0 complex.
From the information in the preceding paragraph,
it would seem reasonable to conclude that histidines
are essential for the pH-dependent activity of IF1,
but this is challenged by the results of a study testing
another hypothesis. Based upon the observation that
bovine IF1 could be cross-linked to the F1 domain L
subunit residues 394^495 and that this sequence has
modest homology to residues 22^46 of the inhibitor
protein, Stout et al. [55] proposed that peptides cor-
responding to residues 394^495 of the L subunit
would mimic IF1 and inhibit ATP hydrolysis. Sup-
porting this hypothesis is the activity of a peptide
corresponding to residues 394^413 of the L subunit,
which had modest potency (IC50 = 20 WM) relative
to the IF1 22^46 peptide or intact IF1. However,
the potency of both peptides decreased about 20-
fold as the pH was increased from 6.5 to 8.0 even
though neither peptide contained a histidine. The
pH-dependent activity of the IF1 22^46 peptide was
also observed by Papa et al. [52]. There are no ob-
vious experimental di¡erences to account for the
contrasting results between this study and the sys-
tematic testing of histidines by site-directed mutagen-
esis, but it appears that the pH-dependent activity of
IF1 cannot be simply attributed to its histidine resi-
dues.
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6. Conformational changes
When algorithms used to predict secondary struc-
ture are applied to the amino acid sequences in Fig.
1, the prediction is that IF1 adopts a predominantly
K-helical structure [12,39,54]. This has been con-
¢rmed at pH 8.0 for IF1 puri¢ed from bovine [5]
or bu¡alo heart [58,59] and recombinant bovine
[12] or rat [39] IF1. However, as the pH is dropped
from 8.0 to around 6.7 the helical content of re-
combinant rat IF1 goes from 62% to 50% [39], re-
spectively, and cannot be measured in bu¡alo heart
IF1 [59]. These observations have been the basis of
an IF1 structure-function model with an inverse cor-
relation between helical content and IF1 activity as a
function of pH.
The pH-dependent helical content of bovine IF1
contradicts this model, where no signi¢cant changes
in secondary structure could be measured between
pH 8.0 and 6.7 [12]. It was noted that the secondary
structure and stability of recombinant bovine IF1
could be profoundly in£uenced by ionic strength
and protein concentration. The circular dichroism
measurements made with bovine IF1 were near the
maximum inhibitory concentration (1^2 WM), while
those using recombinant rat IF1 used 63 WM inhib-
itor protein [39]. When measurements were repeated
using concentrations of rat IF1 more comparable to
the study with bovine IF1, rat IF1 still lost helical
content between pH 8.0 and 6.7 [54]. While it is
di⁄cult to ignore the changes in secondary structure
observed as a function of pH with bu¡alo and rat
IF1, the absence of an e¡ect with bovine IF1 and the
fact that these changes are observed in the absence of
enzyme make the relevance to the inhibitory mecha-
nism of IF1 disputable.
The con£icting results described in preceding sec-
tions concerning the minimal inhibitory IF1 se-
quence, the role of histidines in IF1 function, and
the relevance of conformational changes make it dif-
¢cult to formulate consensus models for IF1 struc-
ture-function relationships. Besides the possible dif-
ferences in experimental conditions discussed, it must
not be ignored that a leap of faith is taken that mu-
tant proteins and peptide fragments of IF1 will cor-
rectly assume the structure and function of the intact
protein. As with any other contemporary structure-
function study a high-resolution structure of IF1,
preferably bound to the F1 domain, will be required
to accurately interpret these discrepancies. It is very
likely that the conserved amino acids between resi-
dues 20 and 50 will play a critical role in this inter-
pretation.
Although the level of information regarding IF1
structure-function relationships provided by re-
combinant sources of the protein has been less than
satisfying, clones of IF1 genes open up other exciting
possibilities around our understanding of this pro-
tein. The human IF1 cDNA [38] could be used to
examine the tissue distribution and level of expres-
sion of IF1 under various physiological or disease
conditions. The cloning of the murine IF1 gene [40]
raises the possibility of studying the physiological
role of this protein via transgenic or knockout
mice. The following sections will discuss hypotheses
concerning the physiological role of IF1, but ¢rst
methods for determining the methods for determin-
ing IF1 protein levels in mitochondria will be exam-
ined.
7. Determining the mitochondrial concentration of IF1
Two approaches have been taken to estimate the
amount of IF1 protein in mitochondria. Antibodies
against bovine IF1 have been developed for radio-
immunoassay [60], but this method has some limita-
tions. The comparison of IF1 content between species
can be compromised, especially if rabbit or mouse is
involved. In addition, only the total amount of IF1
rather than the amount of active IF1 can be esti-
mated by this method.
The more conventional approach has been to esti-
mate IF1 levels in mitochondria by functional assays
of their activity against a standard species source of
enzyme. This was originally pioneered by Horstman
and Racker [13] using IF1-depleted bovine heart sub-
mitochondrial particles (SMP) as an enzyme source,
and has been improved upon using rat heart SMP
[61^63]. IF1-depleted rat heart submitochondrial par-
ticles are prepared using the procedure developed for
bovine heart ‘A’ particles (sonicate mitochondria at
pH 9.2 in the absence of MgWATP followed by di¡er-
ential centrifugation) and IF1 is prepared by alkaline
extraction of mitochondria from various animal and
tissue sources. Rouslin systematically demonstrated
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that IF1-depleted rat heart SMP give more linear
titrations of bovine or rat IF1 than bovine heart
‘A’ particles. Although bovine heart ‘AS’ particles
(‘A’ particles ¢ltered through Sephadex) were com-
parable to rat heart SMP for linear titrations, there
are seasonal e¡ects on the activity of bovine heart
mitochondria.
The rat heart SMP titration method has been used
to measure IF1 levels in cardiac mitochondria from
several species relative to their F1F0-ATPase activity.
Rouslin et al. [62,64^66] have grouped these species
into three regulatory classes according to heart rate,
IF1 content or IF1 a⁄nity. The ¢rst group includes
rabbits and physically larger species (e.g., pig, hu-
man, cow) that have a heart rate of less than 250
beats/min and a ‘full IF1 complement’, which means
these species contain approx. 1 mole of IF1 per mole
of F1-ATPase. The second group includes rodents
such as mice and rats that have a ‘fast’ heart rate
(i.e., s 250 beats/min) and less than 1 mole of IF1
per mole of F1-ATPase. Guinea pigs represent the
third group, which have a heart rate of approx.
250 beats/min and a full complement of IF1, but
fail to show a marked inhibition of the ATPase dur-
ing ischemia. The correlation of heart rate and IF1
content will be discussed later in the context of myo-
cardial ischemia.
8. Possible pathophysiological roles for IF1
It is conceivable that IF1 could play an important
pathophysiological role in any disease that involved
ATP hydrolysis by the F1F0-ATPase. A recent study
in rats has correlated an increase in IF1 and gluta-
thione levels by propylthiouracil induction with pre-
venting the hepatotoxicity caused by an acetamino-
phen metabolite, paracetamol [67]. However, it has
not been demonstrated that ATP hydrolysis through
the F1F0-ATPase plays a part in the pathophysiology
of this condition and that the IF1 protein is a deter-
minant in regulating this activity. Most investigations
into the pathophysiological role of IF1 and the F1F0-
ATPase have been done in the context of myocardial
ischemia, which will be discussed in greater detail
later, but other tissue types as well as tumor growth
may be relevant.
There are several interesting studies on the role of
IF1 in tumor cells. It appears the ATPase activity of
the F1F0-ATPase might be more tightly regulated in
murine Ehrlich ascites carcinoma cells than in rat
thymocytes since oligomycin is not as e¡ective in
slowing down ATP hydrolysis in the presence of a
respiratory uncoupler [68]. The IF1 content in Zajde-
la hepatoma and Yoshida sarcoma cell mitochondria
was 2^3-fold higher than in rat heart or liver mito-
chondria [69], and in the human breast cancer cell
line T-47D the total heat-stable IF1 activity was sig-
ni¢cantly higher than in human ¢broblasts [70].
Although studies such as these have prompted inter-
esting speculation about the role of IF1 in tumor
metabolism [71], more de¢nitive studies are needed
to ¢rmly establish this role. It would be interesting to
see if IF1 expression in tumor cells is under transcrip-
tional control by a hypoxia-sensitive transcription
factor such as the hypoxia inducible factors HIFK
or HIFL [72].
The absence of IF1 is known to occur in one type
of mitochondrial myopathy, but it is not clear
whether the defect in IF1 can be attributed to the
symptoms of this disorder. Luft’s disease was the
¢rst mitochondrial myopathy diagnosed in 1958
[73] and only one other case has been reported since
then [74]. The disorder is characterized clinically by a
non-thyroidal hypermetabolism and morphologically
by mitochondria with densely packed cristae [75,76].
Yamada and Huzel could not measure any IF1 ac-
tivity in ¢broblasts cultured from the skeletal muscle
of one of the Luft’s patients, and could not detect
any IF1 using an antibody that readily detected the
protein from normal human ¢broblasts [70]. Oxida-
tive phosphorylation in mitochondria isolated from
the skeletal muscle of Luft’s patients is ‘loosely
coupled’ (i.e., addition of ADP does not stimulate
oxygen consumption), which is consistent with the
increased mitochondrial cristae density to compen-
sate for less e⁄cient ATP production. However, the
loosely coupled oxidative phosphorylation seen in
Luft’s mitochondria is not consistent with the ab-
sence of IF1 since this protein is believed to be in-
active during conditions of ATP synthesis. Perhaps
this indicates an unknown property of IF1, but the
loosely coupled oxidative phosphorylation seems
more likely to be attributable to an uncoupler pro-
tein [77,78] or a defect in calcium recycling between
the cytosol and mitochondria [75].
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9. IF1 and ATP conservation in myocardial ischemia
Myocardial ischemia exists when the supply of
oxygen is insu⁄cient to meet the myocardial demand
for oxygen. Imbalances between oxygen supply and
demand span a large range and therefore myocardial
ischemia cannot be viewed as a single syndrome and
biochemical pathways involved in the pathogenesis
of low-grade ischemia are likely to be very di¡erent
from those involved in severe ischemia. Patients suf-
fering from chronic stable angina pectoris have nor-
mal resting coronary blood £ow, but have insu⁄cient
blood £ow reserve to meet increased energy demand,
although the oxygen supply/demand imbalance is in-
su⁄cient to cause severe contractile dysfunction or
necrosis. In more severe forms of ischemia, blood
£ow is su⁄ciently impaired that ATP production
through oxidative phosphorylation is signi¢cantly re-
duced. Oxidative phosphorylation produces the great
majority of ATP necessary for contractile function as
well as maintenance of ionic homeostasis, therefore
the heart is very susceptible to blood £ow limitation.
ATP production from anaerobic glycolysis alone can
only maintain ionic homeostasis for short periods of
time and if such a state should continue without
reperfusion of the tissue, necrosis will occur. Severe
ischemia, su⁄cient to impair oxidative phosphory-
lation, causes immediate reduction (or cessation) of
contractile function because the heart only has a
su⁄cient reserve of high energy phosphates to main-
tain several beats. While reduction of contractile
function will certainly reduce energy demand, ATP
still drops as glycolysis is unable to keep up with
other ATPase which are still operating. Therefore,
the rate of onset of irreversible damage is primarily
determined by the rate of energy depletion in these
severely ischemic hearts.
Paradoxically, severely ischemic hearts do not use
ATP e⁄ciently and therefore ATP is ‘wasted’ in that
no useful work is produced from such hydrolysis and
therefore the onset of irreversible damage probably
occurs unnecessarily fast. Evidence that ATP can be
more e⁄ciently used in ischemic myocardium comes
from several approaches. Agents such as ATP-sensi-
tive potassium channel openers conserve myocardial
ATP while also conserving contractile function, sug-
gesting an improved e⁄ciency of energy utilization
during ischemia [79]. Depolarizing cardioplegic solu-
tions also reduce the rate of ATP depletion and exert
protective e¡ects. Even more direct evidence comes
from the work showing the importance of the mito-
chondrial F1F0-ATPase in contributing to futile cy-
cling of ATP or wasteful ATP hydrolysis in severely
ischemic heart [80,81]. This was determined using
pharmacologic inhibitors of this enzyme such as oli-
gomycin and the role of this enzyme in the patho-
genesis of ischemic injury and energy balance will be
discussed in more detail below.
While mitochondrial ATP synthase contributes ap-
prox. 90% of the ATP required by normally beating
myocardium, it becomes a potent ATP hydrolytic
enzyme under ischemic conditions [1,82,83]. This
ATPase activity has been hypothesized to cause ap-
prox. 50^80% of ATP hydrolysis in severely ischemic
heart depending on the species [84]. Such ATP hy-
drolysis would seem to serve no useful purpose and is
therefore wasted. Ischemic and postischemic (reper-
fused) hearts are known to be ine⁄cient meaning
that they consume oxygen and energy without pro-
ducing proportional amounts of work. The impor-
tance of mitochondrial ATPase in ATP depletion
during ischemia varies by species and may be depen-
dent on the function and expression of IF1 protein in
each species [84].
In slow heart rate species such as dog, man, and
rabbits, the amount of ATP wastefully hydrolyzed by
mitochondrial ATPase is signi¢cantly reduced by the
reversible binding of IF1 to the ATPase when the
mitochondrial membrane potential is dissipated (mi-
tochondria are in a de-energized state) [84]. In species
such as dog, the degree of ATPase inhibition from
IF1 is thought to be approx. 50% [84]. The binding of
IF1 appears to be modulated by pH such that bind-
ing is enhanced at the reduced pH values that might
be expected to occur during severe ischemia [62,85].
The calculated ATP depletion rate when there is no
inhibition of ATPase is similar to the rate observed
in ischemic dog hearts in which IF1 binding was
prevented by maintaining a neutral pH in the myo-
cardium (see review in [84]). The binding of IF1 to
the ATPase is rapidly reversed and bound IF1
quickly dissociates upon re-energization of the mito-
chondria (as would be seen upon reperfusion). This
would account for the relatively rapid recovery of
ATP during reperfusion following a sublethal ische-
mic episode. Of course, irreversibly damaged myo-
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cytes will not completely replenish ATP and such
damage is associated with swollen and calcium over-
loaded mitochondria [86]. Severely damaged myocar-
dium can partially replenish their ATP, at least for a
short time, but the myocardium becomes very ine⁄-
cient and consumes oxygen without a commensurate
increase in useful work [87]. The mechanism for this
reperfusion ine⁄ciency is unknown, but may be re-
lated to futile calcium cycling [87].
Fast heart rate species such as rats express much
less IF1 than dogs and therefore signi¢cantly less in-
hibition of ischemic ATPase is observed in these spe-
cies [88,89]. The rate of ATP depletion in ischemic
rat hearts is much greater than that observed in dog
or rabbit hearts [80]. Similarly, the time to ischemic
contracture formation occurs in approx. 17 min com-
pared to 40^45 min in rabbits [90]. Contracture is the
reduced cardiac compliance (measured as an increase
in end diastolic pressure) observed during ischemia
and is thought to be due to rigor bond formation
secondary to ATP depletion. While these data sug-
gest that the mitochondrial ATPase in rats is a crit-
ical determinant of ATP depletion rate, data from
Rouslin et al. [80] also suggest that non-mitochon-
drial ATPase activities are signi¢cantly higher in rats
than in dogs and this could also account (at least in
part) for enhanced ATP hydrolysis rates. Other fast
heart rate species such as guinea pig express higher
levels of IF1, but it apparently binds to the ATPase
with lower a⁄nity and therefore the degree of ATP-
ase inhibition is not as great as seen in dogs [84].
Studies using the selective F1F0-ATPase inhibitor
oligomycin show that mitochondrial ATPase activity
is responsible for signi¢cant ATP hydrolysis in ische-
mic myocardium. Oligomycin will inhibit both the
ATP synthase and ATPase activities, therefore it
would be expected to reduce ATP under normoxic
conditions while it would reduce the rate of ATP
depletion during ischemia. Studies done by Jennings
et al. [81] showed that oligomycin signi¢cantly re-
duced the rate of ATP depletion in canine hearts
between 15 and 90 min into ischemia. Their proce-
dure consisted of placing blocks of myocardium into
plastic bags, which were then subjected to various
intervals of ischemia. Rouslin et al. [80] found that
oligomycin reduced the rate of ATP depletion during
total ischemia in retrogradely perfused dog hearts,
further suggesting that IF1 inhibition of the mito-
chondrial ATPase is not complete even during severe
ischemia. An interesting ¢nding in this study was
that oligomycin was not as e¡ective in inhibiting
ATP depletion rate in rat hearts and the authors
suggested that higher non-mitochondrial ATPase ac-
tivity as well as signi¢cantly higher glycolytic rates in
rat hearts reduced the impact of the mitochondrial
ATPase. Studies from our laboratory showed that
oligomycin signi¢cantly conserved ATP during total
global ischemia in rat hearts [90] as did a recent
study by Vuorinen et al. [91].
While mitochondrial ATPase activity appears to
play an important role in energy depletion during
myocardial ischemia, much more needs to be
learned. It is not apparent how ischemic the hearts
must be before the mitochondrial ATPase activity
becomes signi¢cant. It is presumed that oxidative
phosphorylation must be signi¢cantly impaired to
see the reversal of ATP synthase activity to ATP
hydrolase activity. Such impaired oxygen delivery is
seen only with signi¢cant coronary blood £ow reduc-
tions on the order of 80^90% £ow reduction. It is
therefore unlikely that inappropriate ATP depletion
secondary to mitochondrial ATPase activity is an
important contributor to the pathogenesis of ‘low
£ow’ conditions such as stable angina pectoris, but
becomes more important in severe ischemic disease.
10. IF1 and preconditioning
Ischemic preconditioning is the profound resis-
tance to ischemia observed in tissue following brief
periods of sublethal ischemia. Most studies in this
area have been concerned with myocardial ischemia,
although preconditioning has also been observed in
skeletal muscle and brain. Numerous mechanisms
have been proposed including receptor-mediated
processes such as adenosine, catecholamines, and
ATP-sensitive potassium channels and the involve-
ment of protein kinase C appears to be involved
with the signal transduction process (see review in
[92]). Several other pathways have been proposed
and presently, it is not clear how these pathways
are interconnected. Preconditioning appears to be
present in humans [93] and therefore there is cur-
rently great interest in determining the mechanism
of this interesting phenomenon.
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Early studies by Murry et al. [94] showed that
preconditioning in dogs is associated with a slowing
of energy metabolism characterized by a slower rate
of ATP depletion during ischemia. The precondi-
tioned dog hearts also showed a slowed rate of gly-
cogen utilization and a concomitant reduction in lac-
tate accumulation. Interestingly, several investigators
have shown preconditioning in rat hearts to be asso-
ciated with an enhanced rate of ATP depletion dur-
ing ischemia [90,95] or no e¡ect [96]. Studies from
our laboratory [90] and Asimakis et al. [95] not only
showed enhanced ischemic ATP depletion following
preconditioning (Fig. 2), but also showed a reduction
in time to onset of ischemic contracture, which is
consistent with ATP depletion. Nevertheless, precon-
ditioning in the rat hearts caused signi¢cant posti-
schemic cardioprotection as determined by recovery
of contractile function, reduced necrosis, and en-
hanced recovery of ATP.
It was therefore of great interest that a study by
Vuorinen et al. [91] showed that preconditioning in
isolated rat hearts displayed a reduced rate of ische-
mic ATP depletion, which was accompanied by an
inhibition of mitochondrial ATPase during ischemia.
These investigators hypothesized that the mitochon-
drial ATPase inhibition by IF1 may be involved in
this protective mechanism. This is particularly inter-
esting in light of the ¢ndings of Rouslin et al. [84],
suggesting that IF1 is not important in fast heart rate
species such as rat. Studies from our laboratory
showed that the protective e¡ects of preconditioning
in isolated rat hearts were not associated with mito-
chondrial ATPase inhibition (Fig. 3) or ATP conser-
vation [90]. A study by Vander Heide et al. [97]
showed that preconditioning in dogs was associated
with a reduced rate of ischemic ATP depletion, but
that mitochondrial ATPase inhibition was not in-
volved in this protective mechanism.
The mechanism of preconditioning is currently an
intensively studied topic, although the precise mech-
anism is still elusive. Multiple mechanisms in di¡er-
ent species may be involved which complicates our
understanding of this interesting phenomenon. A
role for inhibition of ischemic mitochondrial ATPase
remains a potentially exciting mechanism, although
more studies are needed to further substantiate this
hypothesis. Thus far, two studies have not shown
Fig. 3. E¡ect of preconditioning on ATP hydrolase activity of
rat heart mitochondria F1F0-ATPase in submitochondrial par-
ticles [90]. Baseline, before preconditioning or sham treatment;
Precond, after preconditioning; 5P and 10P ischemia, 5 and 10
min into prolonged ischemia; 30P reperfusion, 30 min into re-
perfusion.
Fig. 2. E¡ects of three periods of 5 min of global ischemia sep-
arated by 5 min of reperfusion (3U5 preconditioning) on myo-
cardial ATP concentrations in isolated rat hearts [90]. Samples
were taken after 5 min of reperfusion following a ¢nal precon-
ditioning episode (POST-PREC) and 5, 10, 15 or 20 min into
prolonged ischemia (5P, 10P, 15P and 20P ISCH) and 30 min of
reperfusion (30P REPER) after 20 min of ischemia. *Signi¢-
cantly di¡erent from vehicle (P6 0.05).
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this ATPase to be important while one study shows a
positive e¡ect.
11. Conclusion
Our understanding of the molecular events of oxi-
dative phosphorylation has been greatly enhanced
over the past decade by solving the high-resolution
structures of a number of mitochondrial proteins
that participate in this process [98]. Similarly, under-
standing the molecular events that dictate regulation
of the mitochondrial F1F0-ATPase by IF1 will re-
quire at least the same type of information. The ki-
netic and biophysical studies performed on IF1 indi-
cate this protein could have an important role in
determining whether a cell can survive the metabolic
insult of oxygen deprivation, but the importance of
this protein to the pathology of ischemia-related dis-
ease has not been de¢nitively established. The pur-
pose of this review was not only to summarize and
discuss recent studies investigating this protein, but
also to suggest studies that could shed further light
on our understanding of IF1 at the molecular, cellu-
lar and physiological levels.
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